Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 7;114(9):827–839. doi: 10.1159/000535385

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s). Published by S. Karger AG, Basel

This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

PMC Copyright notice

Fig. 2. — Correlation between circulating Treg levels, treatment response, and hPFS in GEP-NET patients receiving TAE treatment. a Representative CT images: CT images illustrate representative cases of patients achieving partial response (PR), stable disease (SD), or progressive disease (PD) after TAE treatment. b Treg levels in responders versus nonresponders: comparison of Treg levels in patients with favorable responses (PR, n = 34) and unfavorable responses (SD + PD, n = 17) to TAE. Data are presented as medians with interquartile ranges. ***p < 0.001. Kaplan-Meier Survival Curves: Kaplan-Meier curves depicting hepatic progression-free survival (PFS) in GEP-NET patients with high (n = 14) or low (n = 37) levels of Tregs. The stratification is based on the cutoff value of 8.975%, as determined by CART analysis.